Shares of Arcturus Therapeutics Holdings Inc. (ARCT) are rising above 15% in pre-market today, after the company reported positive immunogenicity data from its preclinical study for its COVID-19 Vaccine. These data for LUNAR-COV19 were measured by Duke-NUS Medical School in Singapore.
Pad Chivukula, Chief Scientific Officer of Arcturus Therapeutics, said, "These data show that Arcturus' STARR mRNA is superior to conventional mRNA at all equivalent doses and timepoints. Self-replicating mRNA significantly increases spike protein expression, yielding many-fold higher seroconversion rates. The results at the 2 µg dose suggest LUNAR-COV19 has the potential to immunize millions more people."
The stock has been trading between $5.70 and $23.64 in the past one year, and closed Friday's trade at $22.57, up $2.06 or 10.04%. ARCT is currently trading at $25.99, up $3.42 or 15.15% in the pre-market trading session.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.